DrugPatentWatch Database Preview
Exelixis Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for EXELIXIS INC, and when can generic versions of EXELIXIS INC drugs launch?
EXELIXIS INC has one approved drug.
There are six US patents protecting EXELIXIS INC drugs.
There are one hundred and forty-five patent family members on EXELIXIS INC drugs in twenty-nine countries and seventeen supplementary protection certificates in fourteen countries.
Summary for Exelixis Inc
| International Patents: | 145 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Exelixis Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | 10,034,873 | Start Trial | Start Trial | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 8,497,284 | Start Trial | Start Trial | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 9,724,342 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Exelixis Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 4638436 | Start Trial |
| Japan | 2010265302 | Start Trial |
| Japan | 6542429 | Start Trial |
| Australia | 2016247044 | Start Trial |
| European Patent Office | 3329918 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Exelixis Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2213661 | 1490053-4 | Sweden | Start Trial | PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/13/890 20140326 |
| 2213661 | C20140029 00117 | Estonia | Start Trial | PRODUCT NAME: KABOSANTINIIB;REG NO/DATE: K(2014)2043 (LOPLIK) 26.03.2014 |
| 2213661 | CR 2014 00039 | Denmark | Start Trial | PRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140326 |
| 2213661 | 583 | Finland | Start Trial | |
| 2213661 | 122014000091 | Germany | Start Trial | PRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
